BioCentury | Sep 18, 2020
Finance

Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing

...der Vliet told BioCentury. “You essentially get two immune effector cells triggered with one bispecific engager.”Sanofi...
BioCentury | Sep 18, 2020
Product Development

Genentech finds right endpoint to show IL-6 benefit in COVID-19

...the Phase III COVACTA trial. Similarly, Kevzara sarilumab from partners Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi...
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...EP547 for cholestatic and uremic pruritis alongside a $77.5 million series B round led by Sanofi...
...Inc., chief business and principal financial officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), and chief strategy officer of Sanofi...
BioCentury | Sep 15, 2020
Product Development

Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

...Actemra tocilizumab from Roche (SIX:ROG; OTCQX:RHHBY) and Kevzara sarilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi...
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...Therapeutics B.V. as chief regulatory and commercialization officer, a newly established role. Schuring joins from Sanofi...
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...immune response by limiting inflammatory side effects. In mice given the adjuvant CpG and vaccinated with Sanofi...
BioCentury | Sep 9, 2020
Product Development

Data Bytes: Btk race in MS heats up as Roche enters Phase III

...start Phase III testing in the indication, behind evobrutinib from Merck KGaA (Xetra:MRK) and SAR442168, which Sanofi...
...billion takeout of Principia Biopharma Inc. (NASDAQ:PRNB) announced last month (see “Via $3.4B Principia Takeout, Sanofi...
...early to disclose a timeline.  TARGETSBtk – Bruton’s tyrosine kinase Stephen Hansen fenebrutinib (GDC-0853, RG7845) PRN2246, SAR442168 evobrutinib (M2951, MSC2364447C) Sanofi Merck...
BioCentury | Sep 9, 2020
Deals

‘Transformational’ deal with Bayer, $239M series D expand Recursion’s reach into fibrosis

...deal with Sanofi (Euronext:SAN; NASDAQ:SNY), which was Sanofi...
BioCentury | Sep 8, 2020
Politics & Policy

As biopharmas pledge scientific transparency, scrutiny intensifies ahead of FDA’s COVID-19 vaccines panel

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Moderna Inc. (NASDAQ:MRNA), Novavax Inc. (NASDAQ:NVAX) and Sanofi...
BioCentury | Sep 5, 2020
Product Development

Moderna pushes for diverse Phase III as COVID-19 vaccine program nears enrollment target

...Plus €252 million for CureVac, J&J’s challenge data and GSK-Sanofi vaccine enters clinic By Elizabeth S. Eaton...
...vaccine; Johnson & Johnson (NYSE:JNJ) reported a single dose of its vaccine protected hamsters; and partners Sanofi...
...the vaccinated hamsters, which were also protected against death.J&J is testing the vaccine in a Phase I/IIa trial.Sanofi...
Items per page:
1 - 10 of 6657